AR118601A2 - Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral - Google Patents
Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oralInfo
- Publication number
- AR118601A2 AR118601A2 ARP200100962A ARP200100962A AR118601A2 AR 118601 A2 AR118601 A2 AR 118601A2 AR P200100962 A ARP200100962 A AR P200100962A AR P200100962 A ARP200100962 A AR P200100962A AR 118601 A2 AR118601 A2 AR 118601A2
- Authority
- AR
- Argentina
- Prior art keywords
- cys
- oral administration
- formulations
- linaclotide
- stable solid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000007787 solid Substances 0.000 title abstract 2
- 102000000820 Enterotoxin Receptors Human genes 0.000 title 1
- 108010001687 Enterotoxin Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 4
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 abstract 3
- 108010024409 linaclotide Proteins 0.000 abstract 3
- 229960000812 linaclotide Drugs 0.000 abstract 3
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 abstract 1
- ISWAQPWFWKGCAL-ACZMJKKPSA-N Cys-Cys-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISWAQPWFWKGCAL-ACZMJKKPSA-N 0.000 abstract 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 abstract 1
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 abstract 1
- 108010069495 cysteinyltyrosine Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
- Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen en la presente formulaciones sólidas estables de linaclotida adecuadas para la administración oral así como métodos para preparar dichas formulaciones. Las formulaciones descritas en la presente contienen un polipéptido que consiste de la secuencia de aminoácidos Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (linaclotida) o una de sus sales farmacéuticamente aceptables. Las formulaciones de linaclotida descritas en la presente son estables y tienen suficiente vida de depósito para fabricar, almacenar y distribuir el fármaco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942208P | 2008-08-15 | 2008-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118601A2 true AR118601A2 (es) | 2021-10-20 |
Family
ID=56267523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100962A AR118601A2 (es) | 2008-08-15 | 2020-04-06 | Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR118601A2 (es) |
| UA (1) | UA104870C2 (es) |
-
2009
- 2009-08-14 UA UAA201103016A patent/UA104870C2/uk unknown
-
2020
- 2020-04-06 AR ARP200100962A patent/AR118601A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA104870C2 (uk) | 2014-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351746A2 (es) | Formulación sólida estable de un polipéptido agonista de receptor gc-c adecuado para administración oral | |
| CY1119243T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
| TW200637615A (en) | Therapeutic peptide formulations with improved stability | |
| MX2010007150A (es) | Formulaciones del factor de von-willebrand recombinante. | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| MX2011011772A (es) | Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina. | |
| WO2010027405A3 (en) | Formulations of gc-c receptor agonist polypeptides | |
| AR078950A1 (es) | Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales | |
| PE20080397A1 (es) | Proteinas de fusion del receptor de productos finales de glicacion avanzada (ragepor sus sigla en ingles), formulaciones, y metodos de uso de las mismas | |
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| AR087070A1 (es) | Proteinas de fusion liberadoras de relaxina y usos de las mismas | |
| JP2013518115A5 (es) | ||
| PH12014501642B1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| WO2009025196A1 (ja) | Foxm1ペプチドおよびこれを含む薬剤 | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| JP2016501866A (ja) | 皮下脂肪生成を刺激するペプチド | |
| AR088727A1 (es) | Peptidos ciclicos con actividad antineoplasica y antiangiogenica | |
| ZA200807027B (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| AR118601A2 (es) | Formulaciones sólidas estables de un receptor gc-c, agonista polipeptídico adecuado para administración oral | |
| UY32054A (es) | Formulación sólida estable de un polipéptido agonista de receptor gc-c adecuado para administración oral. | |
| ECSP11010897A (es) | Formulación sólida estable de un polipéptido agonista de receptor |